Daraxonrasib Pancreatic Cancer: What RevMed’s Breakthrough Means for Patients and Pharma
Decision brief
Answer first · skim in under a minute
Revolution Medicines’ daraxonrasib nearly doubled median survival in a Phase 3 trial for pancreatic cancer, offering a new standard of care. This article analyzes the clinical data, side effect profile, and competitive implications for pharma teams.
Daraxonrasib pancreatic cancer data from Phase 3 RASolute 302 nearly doubled median overall survival versus chemotherapy. Here is what the trial numbers, RAS coverage, and next regulatory steps mean for patients, BD teams, and investors.
Contents9 sections
Key Takeaways
- In RASolute 302 (NCT06625320), median overall survival was 13.2 months on daraxonrasib versus 6.7 months on chemotherapy in the intent-to-treat group (HR 0.40; p<0.0001).
- Median PFS by blinded review was 7.2 months versus 3.6 months in the ITT population; objective response was 31.6% versus 11.2%.
- FDA previously granted Breakthrough Therapy Designation for previously treated metastatic PDAC with KRAS G12 mutations; the drug is still investigational.
- Revolution Medicines plans global filings, including a U.S. NDA path under the Commissioner’s National Priority Voucher pilot, and has an FDA-authorized expanded access protocol.
What did RASolute 302 show for daraxonrasib?
RASolute 302 is a global, randomized, open-label Phase 3 trial of oral daraxonrasib 300 mg once daily versus investigator-choice chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The registry lists about 500 planned participants and dual primary endpoints of PFS and OS in the RAS G12-mutant subgroup.
Company topline and ASCO plenary disclosures reported median OS of 13.2 months versus 6.7 months in the ITT population (HR 0.40; 95% CI 0.30–0.53; p<0.0001). In the RAS G12 population, median OS was 13.2 months versus 6.6 months with the same HR of 0.40. That is a roughly 60% cut in death risk versus chemo.
Source detail appears in the GlobeNewswire ASCO plenary release and the ClinicalTrials.gov NCT06625320 record.
How does daraxonrasib differ from G12C-only RAS drugs?
Approved KRAS G12C inhibitors such as sotorasib and adagrasib cover a small slice of PDAC, where G12C is rare. Daraxonrasib is designed as a multi-selective RAS(ON) inhibitor that can hit common G12D, G12V, G12R, and related variants that drive most PDAC cases.
That breadth matters for BD mapping. A single oral agent that works across RAS genotypes could become a backbone in second-line metastatic PDAC if regulators agree the Phase 3 package is enough. Expansion work in RAS-mutant NSCLC is also in the company’s stated Phase 3 program, but those readouts are separate from RASolute 302.
Key efficacy and safety numbers BD teams should model
- ITT median PFS (BICR): 7.2 months versus 3.6 months (HR 0.49; p<0.0001)
- RAS G12 median PFS: 7.3 months versus 3.5 months (HR 0.45; p<0.0001)
- ITT ORR: 31.6% versus 11.2%; RAS G12 ORR: 33.2% versus 11.8%
- Dose studied: 300 mg oral once daily versus IV chemo options such as GnP, mFOLFIRINOX, nal-IRI+5-FU/LV, or FOLFOX
Company statements describe daraxonrasib as generally well tolerated with a manageable safety profile and no new safety signals at the topline readout. Grade ≥3 adverse-event rates and discontinuation detail should be taken from the peer-reviewed write-up when modeling payer risk, not from press headlines alone. An NEJM report of RASolute 302 is the preferred clinical citation for detailed AE tables.
What remains unproven after the Phase 3 win?
RASolute 302 does not prove first-line benefit, cure rates, or long-term survival beyond the reported medians. It also does not set a U.S. label or price. Claims about multibillion-dollar peak sales remain commercial forecasts, not trial endpoints.
Patient-level stories in trade media can illustrate quality of life, but they are not substitutes for the randomized OS and PFS results. For diligence, stick to the registry design, the company wire numbers, and the NEJM analysis until FDA labeling exists.
What should pharma BD and investors watch next?
Track three near-term gates: completeness of the U.S. NDA package under the Commissioner’s National Priority Voucher pilot, how FDA weighs the ITT versus RAS G12 primary populations, and how expanded access demand shapes early commercial planning. EMA has also moved toward an expedited phased review path based on the same Phase 3 package, per company disclosure.
Reuters coverage of the survival readout confirmed the magnitude of the OS gain for a general investor audience. Internal teams should still reconcile every figure to the GlobeNewswire/NEJM primary texts before using them in models.
Related NovaPharma coverage
- Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough
- Daraxonrasib Doubles Survival in Pancreatic Cancer
- ASCO ‘26: Bispecifics, ADCs, and the RAS Revolution
- Revolution Medicines company profile
Frequently Asked Questions
What is daraxonrasib and how does it work?
Daraxonrasib (RMC-6236) is an investigational oral RAS(ON) multi-selective inhibitor from Revolution Medicines. It targets the active GTP-bound form of mutant and wild-type RAS, covering common G12 variants that drive most pancreatic ductal adenocarcinomas.
What did the RASolute 302 trial show for overall survival?
In the intent-to-treat population, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with investigator-choice chemotherapy (hazard ratio 0.40; p less than 0.0001), a 60% reduction in the risk of death.
Is daraxonrasib FDA-approved for pancreatic cancer?
No. Daraxonrasib is not approved. FDA granted Breakthrough Therapy and Orphan Drug designations for previously treated metastatic PDAC with KRAS G12 mutations, and Revolution Medicines has said it plans NDA submission under the Commissioner's National Priority Voucher pilot.
Primary Sources
Revolution Medicines pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
